Psoriasis

The FDA has accepted Arcutis Biotherapeutics’ supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, the company announced in a press release.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

The National Psoriasis Foundation has announced the honorees for this year’s Commit to Cure Gala, according to a press release.

Veterans experience higher prevalence rates of skin cancer, especially melanoma, and psoriasis compared with nonveterans, according to a study.

Secukinumab was shown to be safe and efficacious in treating psoriasis in patients with skin of color, according to a study.

Zasocitinib, a potent and selective tyrosine kinase 2 inhibitor, safely and effectively cleared psoriasis in a high proportion of patients, according to a study.

Otezla is now available in the U.S. for the treatment of moderate to severe plaque psoriasis in children and adolescents aged 6 years and older, Amgen announced in a press release.

Individuals with moderate to severe psoriasis experience work absenteeism more than those with a mild form of the disease, according to a study.

Guselkumab can effectively and safely treat patients with psoriasis for up to 2 years, according to a study.